Dipyanone is classified as a novel opioid. Novel opioids have been reported to cause psychoactive effects similar to heroin, fentanyl, and other opioids. Novel opioids have also caused adverse events, including death, as described in the literature. Dipyanone is reported to be
slightly less potent that structurally similar opioids methadone and dipipanone.
Literature reports involving dipyanone are limited. Dipyanone is not explicitly scheduled in the United States; methadone is a Schedule II drug and dipipanone is a Schedule I drug.